These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 16847284

  • 1. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Menendez JA, Mehmi I, Lupu R.
    J Clin Oncol; 2006 Aug 10; 24(23):3735-46. PubMed ID: 16847284
    [Abstract] [Full Text] [Related]

  • 2. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
    Menendez JA, Mehmi I, Lupu R.
    Int J Oncol; 2005 Mar 10; 26(3):649-59. PubMed ID: 15703820
    [Abstract] [Full Text] [Related]

  • 3. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L.
    Oncogene; 2008 Aug 28; 27(37):5019-32. PubMed ID: 18469855
    [Abstract] [Full Text] [Related]

  • 4. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
    Jhabvala-Romero F, Evans A, Guo S, Denton M, Clinton GM.
    Oncogene; 2003 Nov 06; 22(50):8178-86. PubMed ID: 14603258
    [Abstract] [Full Text] [Related]

  • 5. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S, Montero JC, Ocaña A, Pandiella A.
    J Natl Cancer Inst; 2010 Sep 22; 102(18):1432-46. PubMed ID: 20811002
    [Abstract] [Full Text] [Related]

  • 6. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
    Arteaga CL.
    J Clin Oncol; 2006 Aug 10; 24(23):3722-5. PubMed ID: 16847283
    [No Abstract] [Full Text] [Related]

  • 7. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA, Vellon L, Lupu R.
    Med Hypotheses; 2005 Aug 10; 64(5):997-1001. PubMed ID: 15780499
    [Abstract] [Full Text] [Related]

  • 8. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D.
    Cancer; 2003 Oct 01; 98(7):1377-85. PubMed ID: 14508823
    [Abstract] [Full Text] [Related]

  • 9. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 01; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 10. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

  • 11. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.
    Cancer Res; 2002 Oct 15; 62(20):5703-10. PubMed ID: 12384528
    [Abstract] [Full Text] [Related]

  • 12. Expression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers.
    Haas S, Gevensleben H, Rabstein S, Harth V, Pesch B, Brüning T, Justenhoven C, Brauch H, Hamann U, Ko YD, Baisch C, Fischer HP, Büttner R.
    Oncol Rep; 2009 Feb 15; 21(2):299-304. PubMed ID: 19148499
    [Abstract] [Full Text] [Related]

  • 13. Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner.
    Vellon L, Menendez JA, Liu H, Lupu R.
    Differentiation; 2007 Nov 15; 75(9):819-30. PubMed ID: 17999741
    [Abstract] [Full Text] [Related]

  • 14. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE, Serrero G.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
    Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC.
    Clin Cancer Res; 1999 Nov 15; 5(11):3653-60. PubMed ID: 10589783
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.